Health, Fitness & Food

In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT Eli Lilly on Thursday reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company’s quarterly earnings topped Wall Street estimates, but sales fell just short as Mounjaro saw lower realized prices.

In this article BMY Follow your favorite stocksCREATE FREE ACCOUNT The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its

Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per

In this article DOCS Follow your favorite stocksCREATE FREE ACCOUNT Piotr Swat | Lightrocket | Getty Images Doximity shares closed up 36% on Friday, a day after the company reported fiscal third-quarter results that beat Wall Street’s expectations for revenue and guidance. Doximity is a digital platform for medical professionals that can help them carry

In this article HIMS Follow your favorite stocksCREATE FREE ACCOUNT The New York Stock Exchange with a Hims & Hers Health banner is pictured in the Manhattan borough of New York City. Carlo Allegri | Reuters Hims & Hers is facing scrutiny from lawmakers over an advertisement for its weight loss offerings that’s slated to

In this article DOCS Follow your favorite stocksCREATE FREE ACCOUNT Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021. Source: NYSE Shares of Doximity popped 25% in extended trading on Thursday after the company reported third-quarter fiscal 2025 results that beat analysts’ expectations for revenue and offered rosy

In this article GOOGL ELV Follow your favorite stocksCREATE FREE ACCOUNT Verily headquarters in San Bruno, California. Courtesy: Verily Verily is selling its stop-loss insurance subsidiary, Granular Insurance Company, to the insurance provider Elevance Health, the Alphabet health tech company confirmed to CNBC on Thursday. Verily is one of Google’s sister companies and operates within

The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024.  Ore Huiying | Bloomberg | Getty Images Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a

In this article NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT It’s been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo’s obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy’s potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo’s

Looking to reduce our exposure to tariffs and China, we’re making changes in the portfolio. We’re exiting our position in Stanley Black & Decker , selling our remaining 510 shares at roughly $86.79 each. We’re buying 50 shares of Home Depot at roughly $409.60. Following the trade, Jim Cramer’s Charitable Trust will own 300 shares

In this article NVO LLY NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Happy

In this article MRK Follow your favorite stocksCREATE FREE ACCOUNT Sopa Images | Lightrocket | Getty Images Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street’s expectations, as the company temporarily paused shipments of a key vaccine into China.  Shares of Merck fell more than 7% in premarket trading Tuesday.

Shana Novak | Stone | Getty Images President Donald Trump’s steep tariffs on Canada, Mexico and China could worsen ex­ist­ing drug shortages in the U.S., raise healthcare costs for patients and threaten cash-strapped generic drugmakers, some drug trade groups warn. Trump on Saturday announced he would impose a 25% tariff on nearly all goods shipped

Reid Hoffman, Partner at Greylock and co-founder LinkedIn, speaks during the WSJ Tech Live conference hosted by the Wall Street Journal at the Montage Laguna Beach in Laguna Beach, California, on October 21, 2024. Frederic J. Brown | Afp | Getty Images LinkedIn co-founder and venture capitalist Reid Hoffman became a billionaire from his business

Shortly after the opening bell, we are selling 50 shares of Danaher at roughly $256.35. Following the trade, Jim Cramer’s Charitable Trust will own 525 shares of DHR, decreasing its weighting to about 3.65% from about 4%. Danaher, Thermo Fisher , and the life sciences and diagnostic tools group are trading nicely higher Tuesday on

Robert Kennedy Jr., U.S. President-elect Donald Trump’s nominee to run the Department of Health and Human Services, arrives at the Hart Senate Office Building on Capitol Hill in Washington, U.S., December 16, 2024.  Benoit Tessier | Reuters As Robert F. Kennedy Jr. faces two days of Senate confirmation hearings this week in his quest to

In this article NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters The Food and Drug Administration on Tuesday approved Novo Nordisk‘s Ozempic to treat chronic kidney disease in patients who also have Type

Robert F. Kennedy Jr., U.S. President Trump’s nominee to be secretary of Health and Human Services, testifies before a Senate Health, Education, Labor, and Pensions (HELP) Committee confirmation hearing on Capitol Hill in Washington, U.S., Jan. 30, 2025.  Nathan Howard | Reuters Robert F. Kennedy Jr., President Donald Trump‘s pick to lead the Department of

In this article VRTX Follow your favorite stocksCREATE FREE ACCOUNT A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters The Food and Drug Administration on Thursday approved Vertex Pharmaceuticals‘ non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction.  Vertex

Robert F. Kennedy Jr., President Donald Trump‘s controversial pick to lead the Department of Health and Human Services, testified Wednesday before a crucial Senate panel, where he faced questions about past vaccine skepticism, his evolving views on abortion and grasp on sprawling federal health programs. Kennedy, 71, appeared first before the Senate Committee on Finance,